Your dog might live longer now
A biotech company called Loyal has developed a drug that slows aging in dogs by targeting the IGF-1 hormone, which has received acceptance from the FDA — marking the first time a regulator has acknowledged aging itself as treatable. The drug is designed for large dog breeds and could be available by 2027. The creator draws a parallel to human biology, suggesting this could eventually pave the way for human anti-aging treatments.
Summary
The transcript covers a major breakthrough in veterinary and biotech science: a San Francisco-based company called Loyal has developed a drug that does not treat a disease but instead slows the aging process itself in dogs. This is notable because it marks the first time the US drug regulator (the FDA) has accepted a drug with this specific purpose — targeting aging rather than a specific illness.
The science behind the drug centers on IGF-1, a growth hormone. The transcript explains that large dog breeds like Great Danes have up to 28 times more IGF-1 than small breeds like Chihuahuas, which is why large dogs grow bigger but live significantly shorter lives (7–10 years vs. 14–16 years). Loyal's drug works by reducing IGF-1 levels in adult dogs. It comes in two forms: an injection every 3 to 6 months for large breeds, and a daily pill for older dogs. The drug has been tested on over 1,300 dogs, and the first prescriptions could be written as early as 2027.
The presenter emphasizes a broader implication that is not widely discussed: for the first time in history, a regulatory body has formally recognized aging as something that can be pharmacologically treated. The presenter also notes that IGF-1 is not unique to dogs — it exists in humans too — suggesting that this veterinary breakthrough could be a precursor to human anti-aging medicine. The video ends with a call to action to join the presenter's WhatsApp community.
Key Insights
- The speaker explains that large dog breeds have up to 28 times more IGF-1 than small breeds, which causes faster growth but significantly shorter lifespans — nearly half that of smaller dogs like Chihuahuas.
- The speaker claims that for the first time in history, a drug regulator has formally accepted that aging itself — not a disease caused by aging — can be treated as a medical target.
- Loyal's drug works by lowering IGF-1 in adult dogs and comes in two forms: an injection every 3 to 6 months for large breeds, and a daily pill for older dogs at home.
- The speaker states the drug has been tested on over 1,300 dogs and the first prescription could be written as early as 2027, after which it could become as routine as vaccines for large breeds.
- The speaker argues that because the same IGF-1 hormone runs through every human body, dogs could be the first patients of anti-aging treatment, with humans potentially being next.
Topics
Full transcript available for MurmurCast members
Sign Up to Access